Loading...

ALDX ALDEYRA THERAPEUTICS INC US FDA Inspections 8-K Filing

LDYR

LDX

ALDEYRA THERAPEUTICS INC

(ALDX)

2025 8-K

FDA Response Received

Management Change

FDA Deadline Extension

Webcast Announcement

Positive Trial Results

FDA Fast Track Approval

New Product Launches

Special Protocol Assessment

New Product Launches

Clinical Trials

Board Appointment

Collaboration Update

Drug Application Resubmission

Loan Agreement Amendment

Management Changes

Open Market Sale Agreement

Slide Presentation at Resea...

Regulation FD Disclosure

Regulation FD Disclosure

Extension of Option Agreement

FDA Update on Drug Candidat...

Option Agreement with AbbVie

FDA Review Issues

Appointments, Changes in Ma...

FDA Response Letter

FDA Inspection Announcement

Financial Results and Corpo...

Regulation FD Disclosure

FDA Accepts NDA for ADX 2191

FDA Accepts NDA for Reproxalap

External Links:

On May 5, 2025, Aldeyra Therapeutics reported achieving the primary endpoint for ocular discomfort in a Phase 3 trial of its dry eye treatment, 0.25% reproxalap, and plans to resubmit a New Drug Application. A conference call regarding this announcement is scheduled for May 6, 2025.

AI Assistant

ALDEYRA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.